Tuesday, July 18, 2023
Boehringer Ingelheim has launched Esgliteo (empagliflozin/linagliptin), a compound therapy of the SGLT-2 inhibitor Jardiance (empagliflozin) and the DPP-4 inhibitor Trajenta (linagliptin).
Esgliteo is its smaller tablet size, measuring approximately 8.1 millimetres. This size is intended to enhance convenience for patients who struggle with swallowing larger pills. Additionally, Esgliteo offers two dosage options to cater to patients in need of additional glycaemic control: 10 mg of empagliflozin combined with 5 mg of linagliptin, or 25 mg of empagliflozin with 5 mg of linagliptin.
Esgliteo brings several benefits as a combination therapy. Firstly, it delivers a superior glucose-lowering effect compared to either medication used alone. In the EMPA-REG OUTCOME study, empagliflozin, the SGLT-2 inhibitor component, demonstrated a significant cardiovascular benefit by reducing the risk of major cardiovascular events (cardiovascular-related death, nonfatal myocardial infarction, or nonfatal stroke) by 14% compared to a placebo.
Esgliteo harnesses the complementary mechanisms of SGLT-2 and DPP-4 inhibitors to achieve enhanced glucose control. In a phase 3 study, Esgliteo exhibited improved glycemic control at week 24 when compared to using empagliflozin or linagliptin alone as monotherapies.
